Rogaratinib
Tier C — Watch / tradeRogaratinib
Targets：FGFR1, FGFR2, FGFR3, FGFR4
Indications (approved)：Sarcoma, Gastrointestinal stromal tumour, Breast cancer, Metastatic breast cancer, Non-small cell lung cancer, Urothelial carcinoma, Bladder cancer, Solid tumour
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ROGAR-001 | 216394-11-5 | 2-methoxy-4-methylbenzenesulfonyl chloride |
| ROGAR-002 | 83485-34-1 | 2-methoxy-4-methylbenzenethiol |
| ROGAR-003 | 2032-35-1 | 2-bromo-1,1-diethoxyethane |
| ROGAR-004 | 1443531-59-6 | (2,2-diethoxyethyl)(2-methoxy-4-methylphenyl)sulfane |
| ROGAR-005 | 1388033-29-1 | 7-methoxy-5-methylbenzo[b]thiophene |
| ROGAR-006 | 1443531-60-9 | (7-methoxy-5-methylbenzo[b]thiophen-2-yl)boronic acid |
| ROGAR-007 | 1443531-66-5 | 4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde |
| ROGAR-008 | 1443531-67-6 | 4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde |
| ROGAR-009 | 5625-67-2 | piperazin-2-one |
| ROGAR-010 | 937049-27-9 | 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile |
| ROGAR-011 | 939808-08-9 | ethyl 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carboxylate |
| ROGAR-012 | 939807-71-3 | (4-aminopyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol |
| ROGAR-013 | 1443531-64-3 | 6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine |
| ROGAR-014 | 1443531-65-4 | 4-amino-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde |
| Rogaratinib | 1443530-05-9 | 4-((4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl)piperazin-2-one |
| Code | CAS No. | Intermediate |
|---|---|---|
| ROGAR-006 | 1443531-60-9 | (7-methoxy-5-methylbenzo[b]thiophen-2-yl)boronic acid |
| ROGAR-009 | 5625-67-2 | piperazin-2-one |
| ROGAR-012 | 939807-71-3 | (4-aminopyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol |
| ROGAR-015 | 1443531-74-5 | (4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol |
| ROGAR-016 | 1443531-75-6 | (4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol |
| ROGAR-017 | 1443531-61-0 | 2-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione |
| ROGAR-018 | 1443531-76-7 | (4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)methanol |
| ROGAR-019 | 1443531-77-8 | 5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine |
| ROGAR-020 | 4408-64-4 | 2,2'-(methylazanediyl)diacetic acid |
| Rogaratinib | 1443530-05-9 | 4-((4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl)piperazin-2-one |
Frequently asked questions
What are the approved indications of Rogaratinib?
Approved indications include: Sarcoma, Gastrointestinal stromal tumour, Breast cancer, Metastatic breast cancer, Non-small cell lung cancer, Urothelial carcinoma, Bladder cancer, Solid tumour.
When does the Rogaratinib patent expire?
No public expiry year is available for Rogaratinib yet; this page updates once verified.
How many synthesis routes are recorded for Rogaratinib?
2 synthesis routes are recorded; the shortest is 6 steps with 184 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Rogaratinib intermediates?
All intermediates in Rogaratinib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Rogaratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07